{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:35:19Z","timestamp":1793968519330,"version":"4.8.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,6]],"date-time":"2011-05-06T00:00:00Z","timestamp":1304640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1639-3","type":"journal-article","created":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T11:14:16Z","timestamp":1304594056000},"page":"1565-1573","source":"Crossref","is-referenced-by-count":25,"title":["Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors"],"prefix":"10.1007","volume":"68","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Beeram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,6]]},"reference":[{"key":"1639_CR1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1349-7006.2003.tb01465.x","volume":"94","author":"M Shionoya","year":"2003","unstructured":"Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94:459\u2013466","journal-title":"Cancer Sci"},{"key":"1639_CR2","unstructured":"Tohgo A, Shionoya M, Iwahana M, Uesugi Y, Jimbo T, Soga T (2002) DJ-927, a novel orally active taxane: 1. Preclinical antitumor activity and toxicity profile. Proceedings of the AACR 43:790 (Abstract 3916)"},{"key":"1639_CR3","doi-asserted-by":"crossref","unstructured":"Chan S, Paridaens R, Awada A, Mukherjee A, Lawton P, Dumez H et al (2004) Efficacy and prediction of response to the new oral taxane DJ-927 in anthacycline <sic> pre-treated advanced breast cancer (ABC). Eur J Cancer Suppl 4 (No.12):193 (Abstract 641)","DOI":"10.1016\/S1359-6349(06)70646-2"},{"key":"1639_CR4","doi-asserted-by":"crossref","unstructured":"Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R et al (2006) A Phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 4081)","DOI":"10.1200\/jco.2006.24.18_suppl.4081"},{"key":"1639_CR5","doi-asserted-by":"crossref","unstructured":"Moore MR, Jones C, Harker G, Lee F, Ardalan B, Saif MW et al (2006) Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 3591)","DOI":"10.1200\/jco.2006.24.18_suppl.3591"},{"key":"1639_CR6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","volume":"55","author":"T Ishikawa","year":"1998","unstructured":"Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F et al (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091\u20131097","journal-title":"Biochem Pharmacol"},{"key":"1639_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CBC.2002.n.004","volume":"2","author":"JF Maher","year":"2002","unstructured":"Maher JF, Villalona-Calero MA (2002) Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2:287\u2013293","journal-title":"Clin Breast Cancer"},{"key":"1639_CR8","unstructured":"Xeloda\u2122 prescribing information. Genentech USA, Inc"},{"key":"1639_CR9","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin Oncol 19:2282\u20132292","journal-title":"J Clin Oncol"},{"key":"1639_CR10","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Cutsem Van","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097\u20134106","journal-title":"J Clin Oncol"},{"key":"1639_CR11","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812\u20132823","journal-title":"J Clin Oncol"},{"key":"1639_CR12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment of solid tumors. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1639-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1639-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1639-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T21:52:56Z","timestamp":1592517176000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1639-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1639-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,6]]}}}